Advertisement

Research Article Free access | 10.1172/JCI119252

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

J Corne, R Djukanovic, L Thomas, J Warner, L Botta, B Grandordy, D Gygax, C Heusser, F Patalano, W Richardson, E Kilchherr, T Staehelin, F Davis, W Gordon, L Sun, R Liou, G Wang, T W Chang, and S Holgate

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Corne, J. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Djukanovic, R. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Thomas, L. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Warner, J. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Botta, L. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Grandordy, B. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Gygax, D. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Heusser, C. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Patalano, F. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Richardson, W. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Kilchherr, E. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Staehelin, T. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Davis, F. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Gordon, W. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Sun, L. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Liou, R. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Wang, G. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Chang, T. in: JCI | PubMed | Google Scholar

University Medicine, Southampton General Hospital, United Kingdom.

Find articles by Holgate, S. in: JCI | PubMed | Google Scholar

Published March 1, 1997 - More info

Published in Volume 99, Issue 5 on March 1, 1997
J Clin Invest. 1997;99(5):879–887. https://doi.org/10.1172/JCI119252.
© 1997 The American Society for Clinical Investigation
Published March 1, 1997 - Version history
View PDF
Abstract

CGP 51901 is a non-anaphylactogenic mouse/human chimeric anti-human IgE antibody that binds to free IgE and surface IgE of IgE-expressing B cells but not to IgE bound to high affinity IgE receptors (Fc epsilonR1) on mast cells and basophils or low affinity IgE receptors (Fc epsilonR2) on other cells. A phase 1 double-blind, placebo-controlled, single dose study with doses of 3, 10, 30, and 100 mg of CGP 51901 was conducted in 33 pollen-sensitive subjects who had raised levels of serum IgE and received either intravenous CGP 51901 or placebo. The administration of CGP 51901 was well tolerated and resulted in a decrease of serum free IgE levels in a dose-dependent manner, with suppression after 100 mg of CGP 51901 reaching > 96%. Time of recovery to 50% of baseline IgE correlated with the dose of administered antibody and ranged from a mean of 1.3 d for the 3 mg to 39 d for the 100 mg dose. Total IgE, comprised of free and complexed IgE, increased as stored and newly synthesized IgE bound to CGP 51901. Complexed IgE was eliminated at a rate comparable with the terminal half-life of free CGP 51901 (11-13 d at all doses). Only one subject showed a weak antibody response against CGP 51901. We conclude that the use of anti-human IgE antibody is safe and effective in reducing serum IgE levels in atopic individuals and provides a potential therapeutic approach to the treatment of atopic diseases.

Version history
  • Version 1 (March 1, 1997): No description
Advertisement
Advertisement